Keyphrases
First Relapse
100%
Immunomodulation
100%
Experimental Autoimmune Encephalomyelitis
100%
Neuroprotection
100%
WIN55,212-2
100%
Axonal Degeneration
83%
High Dose
83%
Demyelination
66%
Microglia
33%
Multiple Sclerosis
33%
T Cells
33%
Th17 Response
33%
Clinical Performance
33%
Interleukin-12 (IL-12)
33%
Macrophages
33%
Neuroprotective
33%
Moderate Dose
16%
Treatment Group
16%
Brain Levels
16%
Disability
16%
Synthetic Compounds
16%
Interleukin-10
16%
Receptor Affinity
16%
Immunomodulatory
16%
Inflammatory Profile
16%
Immunomodulatory Effect
16%
Neurodegenerative
16%
Anti-neuroinflammation
16%
Medicine and Dentistry
Drug Megadose
100%
Nerve Fiber Degeneration
100%
Neuroprotection
100%
Experimental Autoimmune Encephalomyelitis
100%
Demyelination
80%
Microglia
40%
Multiple Sclerosis
40%
T Cell
40%
Macrophage
40%
Neuroprotective Agent
40%
Tumor Necrosis Factor
40%
Receptor Affinity
20%
Interleukin 10
20%
Cannabinoid
20%
Treatment Group
20%
Neuroscience
Nerve Fiber Degeneration
100%
Neuroprotection
100%
Axonal Degeneration
100%
Experimental Autoimmune Encephalomyelitis
100%
T Cell
40%
Macrophage
40%
Multiple Sclerosis
40%
Microglia
40%
Neuroprotective Agent
40%
Cannabinoid
20%
Receptor Affinity
20%
Interleukin 10
20%
Immunology and Microbiology
Nerve Fiber Degeneration
100%
Brain Level
20%